Laura A. Pike

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi et al. · Journal of Clinical Oncology · 2012 · 153 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis

Christine M. Chan, Laura A. Pike, Qiong Zhou et al. · Clinical Cancer Research · 2012 · 114 citations

Medicine, Oncology, Pharmacology +17

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia

Hagop M. Kantarjian, Giovanni Martinelli, Elias Jabbour et al. · Cancer · 2013 · 105 citations · Full text

Medicine, Hematology, Pharmacology +14

Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer

Jennifer A. Morrison, Laura A. Pike, Sharon B. Sams et al. · Molecular Cancer · 2014 · 102 citations · Full text

Medicine, Endocrinology, Oncology +17

Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study

Peter F.A. Mulders, Robert D. Hawkins, Paul Nathan et al. · European Journal of Cancer · 2012 · 80 citations

Medicine, Oncology, Pharmacology +7